Member Login
  1. Stocks
    2. /
  2. Aptose Biosciences Inc. (NASDAQ: APTO)
    3. /

NASDAQ:APTO (Aptose Biosciences Inc.)

About APTO

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

  • Should you invest $1,000 in Aptose Biosciences Inc. right now?

    Before you buy stock in Aptose Biosciences Inc., consider this:

    The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Aptose Biosciences Inc. wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

    Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,058.57!*

    Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 38 percentage points since 2013*.

    See the Top Stocks * Returns as of 2/20/25

    • Aptose Biosciences Inc. (NASDAQ: APTO) Latest News

    Investing

    Aptose Biosciences Climbs 17% to Reclaim Some Losses

    | Amy Legate-Wolfe

    Aptose Biosciences (TSX:APS)(NASDAQ:APTO) recovered 17% after losing 45% this week from results of its drug trial gave investors a wait-and-see…

    Read more »